 |
71 Diseases |  |
105 Trials |
|
105 Trials |  |
2830 News |  |
| «12...26272829303132333435363738 |
- ||| Cyramza (ramucirumab) / Eli Lilly
Enrollment closed, Combination therapy, Monotherapy, Metastases: A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer (clinicaltrials.gov) - Jan 22, 2013
P2, N=141, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217) (clinicaltrials.gov) - Jan 20, 2013
P2, N=51, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Halaven (eribulin mesylate) / Eisai
Enrollment closed, Combination therapy, Metastases: Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 7, 2013
P1, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Halaven (eribulin mesylate) / Eisai
Enrollment change, Combination therapy: A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors (clinicaltrials.gov) - Dec 19, 2012
P1, N=64, Completed, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting N=85 --> 64
- | Halaven (eribulin mesylate) / Eisai, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial, Metastases: A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer (clinicaltrials.gov) - Dec 4, 2012
P1/2, N=63, Recruiting, Sponsor: howard safran
- |||| glembatumumab vedotin (CDX-011) / Celldex
Trial completion, Metastases: EMERGE: A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer (clinicaltrials.gov) - Nov 28, 2012
P2, N=120, Completed, Sponsor: Celldex Therapeutics
N=85 --> 64 Active, not recruiting --> Completed
- Halaven (eribulin mesylate) / Eisai
Enrollment change, Metastases: E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 19, 2012
P2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=66 --> 48
- Halaven (eribulin mesylate) / Eisai, Turalio (pexidartinib) / Daiichi Sankyo
Enrollment open, Metastases: Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Nov 13, 2012
P1/2, N=80, Recruiting, Sponsor: Hope Rugo, MD
N=66 --> 48 Not yet recruiting --> Recruiting
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer (clinicaltrials.gov) - Nov 13, 2012
P2, N=52, Active, not recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer (clinicaltrials.gov) - Oct 10, 2012
P2, N=50, Active, not recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
- Zoptrex (zoptarelin doxorubicin) / AEterna Zentaris
New P2 trial, Metastases: Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer (clinicaltrials.gov) - Sep 30, 2012
P2, N=7, Terminated, Sponsor: AEterna Zentaris
- Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer (clinicaltrials.gov) - Aug 29, 2012
P2, N=30, Recruiting, Sponsor: University of Southern California
- Halaven (eribulin mesylate) / Eisai
Enrollment closed: Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer (clinicaltrials.gov) - Aug 20, 2012
P2, N=74, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- ||||| Halaven (eribulin mesylate) / Eisai
Biomarker, New P2 trial, IO biomarker: NeoEribulin: Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer (clinicaltrials.gov) - Aug 16, 2012
P2, N=200, Recruiting, Sponsor: SOLTI Breast Cancer Research Group
- ||| Halaven (eribulin mesylate) / Eisai
Trial completion, Combination therapy: A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors (clinicaltrials.gov) - Aug 12, 2012
P1, N=64, Completed, Sponsor: Eisai Inc.
Completed --> Active, not recruiting Recruiting --> Completed
- |||| Halaven (eribulin mesylate) / Eisai
Enrollment open, Metastases: Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer (clinicaltrials.gov) - Aug 5, 2012
P2, N=76, Recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Halaven (eribulin mesylate) / Eisai
Enrollment open: Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 (clinicaltrials.gov) - Aug 2, 2012
P2, N=162, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment open, Combination therapy, Metastases: Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination (clinicaltrials.gov) - Jul 18, 2012
P1, N=54, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed: Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S) (clinicaltrials.gov) - Jul 2, 2012
P4, N=500, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer (clinicaltrials.gov) - Jun 5, 2012
P2, N=29, Recruiting, Sponsor: University of Washington
- | Halaven (eribulin mesylate) / Eisai, Turalio (pexidartinib) / Daiichi Sankyo
New P1/2 trial, Metastases: Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - May 9, 2012
P1/2, N=80, Recruiting, Sponsor: Hope Rugo, MD
- ||||| Halaven (eribulin mesylate) / Eisai
New P2 trial: Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 (clinicaltrials.gov) - May 3, 2012
P2, N=162, Recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| Halaven (eribulin mesylate) / Eisai
New P1 trial, Combination therapy, Metastases: Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination (clinicaltrials.gov) - Apr 24, 2012
P1, N=54, Recruiting, Sponsor: Bayer
- Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Enrollment open, Metastases: Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA) (clinicaltrials.gov) - Apr 15, 2012
P2, N=80, Recruiting, Sponsor: German Breast Group
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Halaven (eribulin mesylate) / Eisai
Enrollment change, Metastases: Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 5, 2012
P1, N=21, Completed, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting N=35 --> 21
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Combination therapy: Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer (clinicaltrials.gov) - Apr 3, 2012
P1/2, N=150, Active, not recruiting, Sponsor: Eisai Inc.
N=35 --> 21 Recruiting --> Active, not recruiting
- ||||||| Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes (clinicaltrials.gov) - Apr 3, 2012
P3, N=1102, Completed, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Halaven (eribulin mesylate) / Eisai
Enrollment open, Combination therapy: Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies (clinicaltrials.gov) - Mar 27, 2012
P1/2, N=58, Recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Halaven (eribulin mesylate) / Eisai
Enrollment change, Metastases: E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Mar 18, 2012
P3, N=762, Completed, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting N=1000 --> 762
- ||||| Halaven (eribulin mesylate) / Eisai
New P1/2 trial, Combination therapy: Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies (clinicaltrials.gov) - Mar 13, 2012
P1/2, N=58, Recruiting, Sponsor: University of California, San Francisco
- Halaven (eribulin mesylate) / Eisai
Enrollment change, Metastases: A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 6, 2012
P1, N=6, Completed, Sponsor: Eisai Inc.
N=1000 --> 762 N=10 --> 6
- Halaven (eribulin mesylate) / Eisai
Enrollment change: Phase I Clinical Study of E7389 (clinicaltrials.gov) - Mar 5, 2012
P1, N=15, Completed, Sponsor: Eisai Co., Ltd.
N=10 --> 6 N=24 --> 15
- Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 15, 2012
P2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
N=24 --> 15 Active, not recruiting --> Completed
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer (clinicaltrials.gov) - Feb 14, 2012
P2, N=52, Active, not recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
New P2 trial, Metastases: Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA) (clinicaltrials.gov) - Feb 7, 2012
P2, N=80, Recruiting, Sponsor: German Breast Group
- ||||| Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer (clinicaltrials.gov) - Feb 5, 2012
P2, N=76, Recruiting, Sponsor: SCRI Development Innovations, LLC
- | Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer (clinicaltrials.gov) - Dec 21, 2011
P2, N=47, Recruiting, Sponsor: Emory University
- |||||||||| Onzeald (etirinotecan pegol) / Nektar Therap
New P3 trial, Metastases: The BEACON Study (Breast Cancer Outcomes With NKTR-102) (clinicaltrials.gov) - Dec 12, 2011
P3, N=840, Active, not recruiting, Sponsor: Nektar Therapeutics
- Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies (clinicaltrials.gov) - Nov 3, 2011
P=N/A, N=9, Completed, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Halaven (eribulin mesylate) / Eisai
New P4 trial: Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S) (clinicaltrials.gov) - Oct 31, 2011
P4, N=500, Active, not recruiting, Sponsor: Eisai Co., Ltd.
- ||||| Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217) (clinicaltrials.gov) - Oct 20, 2011
P2, N=51, Active, not recruiting, Sponsor: Eisai Co., Ltd.
- |||||||||| Halaven (eribulin mesylate) / Eisai
New P3 trial, Metastases: A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 17, 2011
P3, N=540, Active, not recruiting, Sponsor: Eisai Inc.
- |||| Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: Study of E7389 for Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Oct 10, 2011
P2, N=81, Completed, Sponsor: Eisai Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Halaven (eribulin mesylate) / Eisai
New P2 trial, Combination therapy: Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer (clinicaltrials.gov) - Sep 21, 2011
P2, N=67, Active, not recruiting, Sponsor: Eisai Inc.
- | Halaven (eribulin mesylate) / Eisai
New P1 trial, Metastases: A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer (clinicaltrials.gov) - Sep 11, 2011
P1, N=24, Active, not recruiting, Sponsor: Eisai Co., Ltd.
- ||||| Cyramza (ramucirumab) / Eli Lilly
New P2 trial, Combination therapy, Monotherapy, Metastases: A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer (clinicaltrials.gov) - Aug 31, 2011
P2, N=141, Active, not recruiting, Sponsor: Eli Lilly and Company
- |||| Halaven (eribulin mesylate) / Eisai
Enrollment open: Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy (clinicaltrials.gov) - Aug 31, 2011
P2, N=148, Recruiting, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Halaven (eribulin mesylate) / Eisai
New P1 trial: An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function (clinicaltrials.gov) - Aug 15, 2011
P1, N=18, Active, not recruiting, Sponsor: Eisai Inc.